DASI Simulations closes $5 million convertible note funding round
Company momentum continues to build after FDA clearance of PrecisionTAVI, the first cleared predictive modeling technology for heart valve replacement
DUBLIN, OHIO, UNITED STATES, February 6, 2024 /EINPresswire.com/ — DASI Simulations, a medical technology start-up offering a novel AI-powered medical platforms to advance toward lifetime management and improved outcomes for structural heart interventions, has closed it $5 million convertible note round. The company has now surpassed $7 million in funds raised.
DASI will use the funds to continue to commercialize and extend its initial product, PrecisionTAVI, and launch new AI-driven products in the structural heart domain.
